2025
Incidence and predictors of nonresponse to intranasal midazolam in children undergoing laceration repair
Martin S, Bauer K, Heyming T, Zhu J, Lee H, Kain Z. Incidence and predictors of nonresponse to intranasal midazolam in children undergoing laceration repair. Academic Emergency Medicine 2025 PMID: 39901057, DOI: 10.1111/acem.15106.Peer-Reviewed Original ResearchSociable temperamentClinical practice implicationsIntranasal midazolam administrationAnxiety ScaleModified Yale Preoperative Anxiety ScaleTemperamentAnxietyLaceration repairIntranasal midazolamProcedural anxietyEmergency departmentChild ageExtremity lacerationsYoung childrenMultivariate logistic regression analysisChildrenAssociated with likelihoodLogistic regression analysisLong delayYale Preoperative Anxiety ScaleNonrespondersLaceration locationCross-sectional studyProportion of childrenNonresponse
2023
Machine learning analysis of pretreatment skin biopsies predicts nonresponse to dupilumab in patients with eczematous dermatitis
Murphy M, Hwang E, Singh K, Lee T, Cohen J, Damsky W. Machine learning analysis of pretreatment skin biopsies predicts nonresponse to dupilumab in patients with eczematous dermatitis. British Journal Of Dermatology 2023, 190: 132-134. PMID: 37818837, DOI: 10.1093/bjd/ljad389.Peer-Reviewed Original ResearchBaseline skin cytokine profiles determined by RNA in situ hybridization correlate with response to dupilumab in patients with eczematous dermatitis
Singh K, Valido K, Swallow M, Okifo K, Wang A, Cohen J, Damsky W. Baseline skin cytokine profiles determined by RNA in situ hybridization correlate with response to dupilumab in patients with eczematous dermatitis. Journal Of The American Academy Of Dermatology 2023, 88: 1094-1100. PMID: 36780951, DOI: 10.1016/j.jaad.2022.12.052.Peer-Reviewed Original ResearchConceptsEczematous dermatitisHistologic featuresTreatment selectionType 1Type 3 inflammationInflammatory skin diseaseCertain histologic featuresSitu hybridization correlatesClinical responseNonresponder groupCytokine profileCytokine stainingAtopic dermatitisCytokine RNAEczematous disordersSitu hybridizationDupilumabIL13 expressionSkin diseasesType 2PatientsDermatitisNonrespondersMolecular heterogeneityImproved response
2022
Keys to Achieving Clinically Important Weight Loss: Perceptions of Responders and Nonresponders in the Clinic and Community Approaches to Healthy Weight Trial
Fay C, Castro I, Velez D, Ruggiero C, O'Connor G, Perkins M, Luo M, Sharifi M, Mini F, Taveras E, Kuhlthau K, Fiechtner L. Keys to Achieving Clinically Important Weight Loss: Perceptions of Responders and Nonresponders in the Clinic and Community Approaches to Healthy Weight Trial. Childhood Obesity 2022, 19: 507-514. PMID: 36315223, PMCID: PMC10698771, DOI: 10.1089/chi.2022.0112.Peer-Reviewed Original ResearchConceptsPediatric weight management interventionsBody mass index improvementWeight management interventionsImportant weight lossUnmet social needsPerspectives of caregiversHealthy weightHealth behaviorsNonrespondersSemistructured guideThematic saturationWeight lossWeight stigmaRespondersMindful eating
2021
Cabozantinib plus immunotherapy combinations in metastatic renal cell and urothelial carcinoma
Meza L, Malhotra J, Favorito C, Pal S. Cabozantinib plus immunotherapy combinations in metastatic renal cell and urothelial carcinoma. Future Oncology 2021, 18: 21-33. PMID: 34766841, DOI: 10.2217/fon-2021-0570.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMetastatic renal cell carcinomaMetastatic urothelial carcinomaTargeted therapyTreatment of metastatic RCCMetastatic renal cellNonresponders to monotherapyRenal cell carcinomaIncrease clinical responsesImmunotherapy combinationsMetastatic RCCUrothelial carcinomaClinical responseCell carcinomaProgressive diseaseIO agentsTreatment optionsRenal cellsImmunotherapyQuality of lifeCabozantinibMonotherapyCarcinomaNovel approachesNonrespondersTherapyDetection of differentially abundant cell subpopulations in scRNA-seq data
Zhao J, Jaffe A, Li H, Lindenbaum O, Sefik E, Jackson R, Cheng X, Flavell RA, Kluger Y. Detection of differentially abundant cell subpopulations in scRNA-seq data. Proceedings Of The National Academy Of Sciences Of The United States Of America 2021, 118: e2100293118. PMID: 34001664, PMCID: PMC8179149, DOI: 10.1073/pnas.2100293118.Peer-Reviewed Original ResearchMeSH KeywordsAgingB-LymphocytesBrainCell LineageCOVID-19CytokinesDatasets as TopicDendritic CellsGene Expression ProfilingGene Expression RegulationHigh-Throughput Nucleotide SequencingHumansMelanomaMonocytesPhenotypeRNA, Small CytoplasmicSARS-CoV-2Severity of Illness IndexSingle-Cell AnalysisSkin NeoplasmsT-LymphocytesTranscriptomeConceptsDA subpopulationsIll COVID-19 patientsImmune checkpoint therapyCOVID-19 patientsSingle-cell RNA sequencing analysisCheckpoint therapyBrain tissueCell subpopulationsRNA sequencing analysisTime pointsSubpopulationsDiseased individualsDistinct phenotypesOriginal studyCell typesAbundant subpopulationSequencing analysisCellsDA measuresPhenotypeImportant differencesNonrespondersPatientsTherapy
2020
Randomized Controlled Trial Testing the Effectiveness of Adaptive “SMART” Stepped-Care Treatment for Adults With Binge-Eating Disorder Comorbid With Obesity
Grilo CM, White MA, Masheb RM, Ivezaj V, Morgan PT, Gueorguieva R. Randomized Controlled Trial Testing the Effectiveness of Adaptive “SMART” Stepped-Care Treatment for Adults With Binge-Eating Disorder Comorbid With Obesity. American Psychologist 2020, 75: 204-218. PMID: 32052995, PMCID: PMC7027689, DOI: 10.1037/amp0000534.Peer-Reviewed Original ResearchConceptsStepped-care treatmentCognitive behavioral therapyWeight loss medicationsBinge-eating disorderStepped careRemission rateWeight lossBehavioral weight lossSignificant weight lossBinge-eating frequencySignificant time effectControlled TrialsTreat analysisTreatment respondersMedicationsPlaceboMixed model analysisClinical practiceNonrespondersPatientsObesityBinge eatingCareMonthsTreatment
2016
Understanding red blood cell alloimmunization triggers
Hendrickson JE, Tormey CA. Understanding red blood cell alloimmunization triggers. Hematology 2016, 2016: 446-451. PMID: 27913514, PMCID: PMC6142457, DOI: 10.1182/asheducation-2016.1.446.Peer-Reviewed Original ResearchConceptsRBC alloimmunizationRed blood cellsRisk factorsBlood cellsWhite blood cellsBlood group antigensPregnancy outcomesAlloantibody formationRBC alloantibodiesRBC transfusionRecipient factorsTransfusion safetyAlloimmunizationAnimal modelsHuman studiesPrevention strategiesDonor plasmaDanger signalsParticular antigenGroup antigensAntigenTransfusionPregnancyNonrespondersCells
2013
Radio‐responsive tumors exhibit greater intratumoral immune activity than nonresponsive tumors
Gerber S, Lim J, Connolly K, Sedlacek A, Barlow M, Murphy S, Egilmez N, Lord E. Radio‐responsive tumors exhibit greater intratumoral immune activity than nonresponsive tumors. International Journal Of Cancer 2013, 134: 2383-2392. PMID: 24154990, PMCID: PMC3949198, DOI: 10.1002/ijc.28558.Peer-Reviewed Original ResearchConceptsRadiation therapyIL-12Immune cellsImmune responseEffectiveness of RTEfficacy of RTCD8 T cellsIntratumoral immune cellsCytokines IL-12Effectiveness of therapyOutcome of radiotherapyEfficacy of treatmentComplete remissionResponsive tumorsCure rateNonresponsive tumorsT cellsImmune activityAntitumor effectsImmune systemCombinatorial treatmentTumor modelColon adenocarcinomaNonrespondersTumors
2012
D-Cycloserine for Treatment Nonresponders With Obsessive-Compulsive Disorder: A Case Report
Norberg M, Gilliam C, Villavicencio A, Pearlson G, Tolin D. D-Cycloserine for Treatment Nonresponders With Obsessive-Compulsive Disorder: A Case Report. Cognitive And Behavioral Practice 2012, 19: 338-345. DOI: 10.1016/j.cbpra.2011.05.002.Peer-Reviewed Original ResearchObsessive-compulsive disorderN-methyl-D-aspartate (NMDA) receptor partial agonist D-cycloserinePartial agonist D-cycloserineThird of patientsD-cycloserineCourse of ERPReuptake inhibitorsCase reportTreatment nonrespondersEffective treatmentPatientsPrior treatmentResponse preventionGreater reductionTreatmentDisordersPresent studyAdequate responseNonrespondersPrevention
1996
Antenatal management of alloimmune thrombocytopenia with intravenous γ-globulin: A randomized trial of the addition of low-dose steroid to intravenous γ-globulin
Bussel J, Berkowitz R, Lynch L, Lesser M, Paidas M, Huang C, McFarland J. Antenatal management of alloimmune thrombocytopenia with intravenous γ-globulin: A randomized trial of the addition of low-dose steroid to intravenous γ-globulin. American Journal Of Obstetrics And Gynecology 1996, 174: 1414-1423. PMID: 9065105, DOI: 10.1016/s0002-9378(96)70582-3.Peer-Reviewed Original ResearchMeSH KeywordsCerebral HemorrhageDexamethasoneDose-Response Relationship, DrugDrug Therapy, CombinationFemaleFetal BloodFetal DiseasesHumansImmunoglobulins, IntravenousIsoantibodiesMaternal-Fetal ExchangePlatelet CountPrednisonePregnancyProspective StudiesSalvage TherapyThrombocytopeniaTreatment OutcomeConceptsIntravenous γ-globulinAlloimmune thrombocytopeniaThrombocytopenic fetusesIntracranial hemorrhageIntravenous gamma globulin treatmentGamma globulin treatmentLow-dose steroidsUtero platelet transfusionsFetal blood samplingMaternal infusionAntenatal managementSevere thrombocytopeniaΓ-globulinPlatelet countPlatelet transfusionsBlood samplingFetal bloodThrombocytopeniaPlatelet increaseDexamethasoneFetusesGm/PrednisoneNonrespondersHemorrhage
1995
Differences between responders and nonresponders to cocaine cues in the laboratory
Avants S, Margolin A, Kosten T, Cooney N. Differences between responders and nonresponders to cocaine cues in the laboratory. Addictive Behaviors 1995, 20: 215-224. PMID: 7484315, DOI: 10.1016/0306-4603(94)00066-2.Peer-Reviewed Original ResearchConceptsDrug cuesGroup differencesDrug-dependent subjectsCocaine-dependent methadone patientsGroups of subjectsMethadone patientsCocaine cravingCocaine dependenceCocaine expectanciesCocaine aversionNonrespondersOne-thirdRespondersCue responsesCravingDemographic variablesSubjectsCurrent studyPatientsDifferences
1979
Phenobarbital treatment in primary biliary cirrhosis. Differences in bile acid composition between responders and nonresponders.
Stellaard F, Bolt M, Boyer J, Klein P. Phenobarbital treatment in primary biliary cirrhosis. Differences in bile acid composition between responders and nonresponders. Translational Research 1979, 94: 853-61. PMID: 501209.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply